Hydroxychloroquine Inhibits Cardiac Conduction in Aged Patients with Nonmalaria Diseases
Background: The COVID-19 pandemic has brought increased focus on hydroxychloroquine (HCQ), as doctors, the medical community, and policymakers around the world attempt to understand how the risks of HCQ weigh against unknown benefits. We aim to evaluate the effects of HCQ on cardiac conduction, thus...
Main Authors: | Yanting Yu, Jianteng Xu, Anni Xie, Sijia Liu, Xiaojian Wang, Runzhang Zhu, Xiaoyan Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2021-04-01
|
Series: | Kidney Diseases |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/515278 |
Similar Items
-
Use of chloroquine and hydroxychloroquine in COVID-19 patients: A dilemma
by: Archana Bhatia, et al.
Published: (2022-01-01) -
The role of hydroxychloroquine in COVID-19: Where do we stand?
by: Ranjit Mohan Anjana, et al.
Published: (2020-01-01) -
QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019
by: Arun R. Sridhar, MBBS, MPH, et al.
Published: (2020-08-01) -
The impact of hydroxychloroquine–azithromycin combination on Tpeak‐to‐end and Tpeak‐to‐end/QT ratio during a short treatment course
by: Nijad Bakhshaliyev, et al.
Published: (2021-07-01) -
Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis
by: Thomas S. Hong, et al.
Published: (2020-11-01)